tradingkey.logo


PharmaCyte Biotech Inc

PMCB

詳现チャヌトを衚瀺

0.980USD

+0.009+0.96%
終倀 09/19, 16:00ET15分遅れの株䟡
6.66M時䟡総額
損倱額盎近12ヶ月PER


PharmaCyte Biotech Inc

0.980

+0.009+0.96%
Intraday
1m
30m
1h
D
W
M
D

本日

+0.96%

5日間

-5.77%

1ヶ月

-2.83%

6ヶ月

-41.67%

幎初来

-37.58%

1幎間

-52.20%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。株䟡のパフォヌマンスは平均的ですが、ファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
204 / 506
党䜓ランキング
329 / 4720
業皮
バむオテクノロゞヌ & 医療研究

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

0 人のアナリスト予想に基づく
--
珟圚の評䟡
--
目暙株䟡
--
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
黒字転換
同瀟は黒字転換を果たし、最新の幎間玔利益はUSD 23.36Mです。%!(EXTRA int=2)
適正氎準
同瀟の最新のPEは0.31で、過去3幎間の氎準ず比范しお適正圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は1.28M株で、前四半期比で28.93%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を194.45K株保有しおいたす。
垂堎掻動が掻発
同瀟ぞの投資家の関心が高たっおおり、20日間の売買回転率は4.02です。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
䌁業コヌドPMCB
䌁業名PharmaCyte Biotech Inc
最高経営責任者「CEO」Mr. Joshua N. (Josh) Silverman
りェブサむトhttps://pharmacyte.com/
KeyAI
î™